# US 2005/0222040 A1 · Vertebrate peptide modulators of lipid metabolism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0222040 A1
- Document ID: US20050222040A1
- Status: Published application
- Kind: A1
- Application number: 10/818,036
- Filed: 2004-04-05
- Published: 2005-10-06
- Earliest claimed: 2004-04-05
- Assignees: BLM Group
- Inventors: Bernice Schacter; Lee Schacter; Michael Zeldin
- Web page: https://patentgrep.com/patent/US20050222040A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 3/04: Anorexiants; Antiobesity agents
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides vertebrate lipid mobilizing peptides, derivative compounds and compositions as well as methods of using such peptides, derivative compounds and compositions for modulating the lipid metabolism of a vertebrate subject.

## Claims

### Claim 1

An isolated vertebrate lipid mobilizing peptide encoded by a vertebrate gene, having the structure:
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 where Xaa1, Xaa2, Xaa3 and Xaa5 are any amino acid residue, Xaa4 is Phe or Leu, Xaa6 is a nonpolar amino acid residue, Xaa7 is an uncharged polar amino acid residue, Xaa9 is Gly or absent and Xaa10 and Xaa11 are present or absent, wherein the vertebrate lipid mobilizing peptide is translated operatively linked to a secretory signal sequence, and wherein the lipid metabolism of a vertebrate cell is modulated in response to contacting the cell with the vertebrate lipid mobilizing peptide.

### Claim 2 (depends on 1)

The isolated vertebrate lipid mobilizing peptide of claim 1 wherein Xaa6 is Ala and Xaa7 is Ser.

### Claim 3 (depends on 1)

The isolated vertebrate lipid mobilizing peptide of claim 1 wherein Xaa2 is Leu.

### Claim 4 (depends on 1)

The isolated vertebrate lipid mobilizing peptide of claim 1 wherein Xaa3 is Asn.

### Claim 5 (depends on 1)

The isolated vertebrate lipid mobilizing peptide of claim 1 wherein Xaa5 is Thr.

### Claim 6 (depends on 1)

The isolated vertebrate lipid mobilizing peptide of claim 1 wherein Xaa8 is Trp.

### Claim 7

An isolated vertebrate lipid mobilizing peptide encoded by a vertebrate KIAA0556 cluster gene, consisting essentially of 8-11 amino acid residues, wherein the vertebrate lipid mobilizing peptide is translated operatively linked to a secretory signal sequence, wherein the lipid metabolism of a vertebrate cell is; modulated in response to contacting the cell with the vertebrate lipid mobilizing peptide.

### Claim 8 (depends on 7)

The isolated vertebrate lipid mobilizing peptide of claim 7 wherein the vertebrate KIAA0556 cluster gene is selected from the group consisting of Hs.30512, D430042O09Rik, LOC361646, Bt.10058, Ssc.6085, Gga.9001, Xl.29814, Dr.16016 and Omy.7157.

### Claim 9 (depends on 7)

The isolated vertebrate lipid mobilizing peptide of claim 7 having the structure: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 where Xaa1, Xaa2, Xaa3 and Xaa5 are any amino acid residue, Xaa4 is Phe or Leu, Xaa6 is a nonpolar amino acid residue, Xaa7 is an uncharged polar amino acid residue, Xaa9 is Gly or absent and Xaa10 and Xaa11 are present or absent.

### Claim 10 (depends on 9)

The isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa6 is Ala and Xaa7 is Ser.

### Claim 11 (depends on 9)

The isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa2 is Leu.

### Claim 12 (depends on 9)

The isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa3 is Asn.

### Claim 13 (depends on 9)

The isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa5 is Thr.

### Claim 14 (depends on 9)

The isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa8 is Trp.

### Claim 15 (depends on 9)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 9 wherein Xaa1 is selected from the group consisting of Gln, Arg, pGlu, and a pyroglutamyl alternative moiety.

### Claim 16 (depends on 15)

The derivative compound of claim 15 wherein the pyroglutamyl alternative moiety selected from the group consisting of L-6-ketopiperidine-2-carbonyl-, (S)-4,5-dihydroorotic acid derivatives, gamma-butyrolactone-gamma-carbonyl-, L-pyro-2-aminoadipyl-, alpha-((1S,2R))-2-methyl-4-oxocyclopentylcarbonyl- and (S)-2-oxoimidazoline-4-carbonyl-derivatives.

### Claim 17 (depends on 9)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 9 wherein at least one of the amino acid residues is derivatized.

### Claim 18 (depends on 9)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 9 wherein at least one of the amino acid residues is conservatively substituted.

### Claim 19 (depends on 9)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 9 wherein at least one of the amino acid residues is replaced by an amino acid not encoded by the genetic code.

### Claim 20 (depends on 1)

A composition comprising the vertebrate lipid mobilizing peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A kit comprising the vertebrate lipid mobilizing peptide of claim 1 and instructions for use.

### Claim 22

A vertebrate lipid mobilizing peptide having the structure Xaa1-Leu-Asn-Xaa4-Thr-Ala-Ser-Trp-Xaa9-Xaa10-Xaa11, wherein Xaa1 is selected from the group consisting of Gln, Arg, and pGlu, Xaa4 is Phe or Leu, Xaa9 is Gly or absent and Xaa10 and Xaa11 are present or absent.

### Claim 23

An isolated vertebrate lipid mobilizing peptide having a sequence selected from the group consisting of SEQ ID NOs:31, 32, 33, 34, 35, 36, 37 and 38.

### Claim 24 (depends on 22)

A derivative compound of the vertebrate lipid mobilizing peptide of claim 22 where Xaa1 is a pyroglutamyl alternative moiety selected from the group consisting of L-6-ketopiperidine-2-carbonyl-, (S)-4,5-dihydroorotic acid derivatives, gamma-butyrolactone-gamma-carbonyl-, L-pyro-2-aminoadipyl-, alpha-((1S,2R))-2-methyl-4-oxocyclopentylcarbonyl- and (S)-2-oxoimidazoline-4-carbonyl-derivatives.

### Claim 25 (depends on 22)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 22 wherein at least one of the amino acid residues is derivatized.

### Claim 26 (depends on 22)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 22 wherein at least one of the amino acid residues is conservatively substituted.

### Claim 27 (depends on 22)

A derivative compound of the isolated vertebrate lipid mobilizing peptide of claim 22 wherein at least one of the amino acid residues is replaced by an amino acid not encoded by the genetic code.

### Claim 28 (depends on 22)

A composition comprising the vertebrate lipid mobilizing peptide of claim 22 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 17)

A composition comprising the derivative compound of claim 17 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 25)

A composition comprising the derivative compound of claim 25 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 25)

A kit comprising the vertebrate lipid mobilizing peptide of claim 25 and instructions for use.

### Claim 32

An isolated peptide having a sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

### Claim 33

An isolated peptide having a sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29.

### Claim 34 (depends on 32)

A composition comprising the isolated peptide of claim 32 and a pharmaceutically acceptable carrier.

### Claim 35 (depends on 33)

A composition comprising the isolated peptide of claim 33 and a pharmaceutically acceptable carrier.

### Claim 36 (depends on 34)

A kit comprising the composition of claim 34 and instructions for use.

### Claim 37 (depends on 35)

A kit comprising the composition of claim 35 and instructions for use.

### Claim 38 (depends on 32)

A vector comprising a nucleotide sequence encoding the peptide of claim 32.

### Claim 39 (depends on 33)

A vector comprising a nucleotide sequence encoding the peptide of claim 33.

### Claim 40 (depends on 38)

A cell comprising the vector of claim 38.

### Claim 41 (depends on 39)

A cell comprising the vector of claim 39.

### Claim 42 (depends on 1)

An antibody immunoreactive to the peptide of claim 1.

### Claim 43 (depends on 7)

An antibody immunoreactive to the peptide of claim 7.

### Claim 44 (depends on 22)

An antibody immunoreactive to the peptide of claim 22.

### Claim 45 (depends on 42)

A diagnostic system of the present invention in kit form comprising a composition comprising a carrier and the antibody of claim 42 or fragments thereof in an amount sufficient to perform at least one assay as a separately packaged reagent and instructions for use of the packaged reagent.

### Claim 46 (depends on 43)

A diagnostic system of the present invention in kit form comprising a composition comprising a carrier and the antibody of claim 43 or fragments thereof in an amount sufficient to perform at least one assay as a separately packaged reagent and instructions for use of the packaged reagent.

### Claim 47 (depends on 44)

A diagnostic system of the present invention in kit form comprising a composition comprising a carrier and the antibody of claim 44 or fragments thereof in an amount sufficient to perform at least one assay as a separately packaged reagent and instructions for use of the packaged reagent.

### Claim 48 (depends on 1)

A method of modulating lipid metabolism of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 1 or a derivative compound thereof.

### Claim 49 (depends on 7)

A method of modulating lipid metabolism of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 7 or a derivative compound thereof.

### Claim 50 (depends on 22)

A method of modulating lipid metabolism of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 22 or a derivative compound thereof.

### Claim 51 (depends on 1)

A method of reducing the body fat of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 1 or a derivative compound thereof.

### Claim 52 (depends on 7)

A method of reducing the body fat of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 7 or a derivative compound thereof.

### Claim 53 (depends on 22)

A method of reducing the body fat of a vertebrate subject comprising the step of administering an effective amount of the peptide of claim 22 or a derivative compound thereof.

### Claim 54 (depends on 1)

A method of reducing the body mass index of a human subject comprising the step of administering an effective amount of the peptide of claim 1 or a derivative compound thereof.

### Claim 55 (depends on 7)

A method of reducing the body mass index of a human subject comprising the step of administering an effective amount of the peptide of claim 7 or a derivative compound thereof.

### Claim 56 (depends on 22)

A method of reducing the body mass index of a human subject comprising the step of administering an effective amount of the peptide of claim 22 or a derivative compound thereof.
